Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJiří MinaříkAJAlexandra JungováYWYuwei Wang

Discussion

Loading...

Member takes

Overview

Data shows progression-free survival in multiple myeloma patients, highlighting the need for new treatment options.

Key Points

  • This research aims to assess survival outcomes for multiple myeloma patients exposed to BCMA-targeted therapies.
  • Data gathered from European MM registries: IUCT, RMG, and TriNetX.
  • Eligible patients previously received PI, IMID, anti-CD38, and anti-BCMA therapy.
  • Survival outcomes were analyzed using Kaplan-Meier and proportional hazards regression.
  • Median time to next treatment was 5.2 months.
  • Median overall survival was 12.5 months.
  • 90.3% of patients were triple-class refractory.

Cite This Study

Minařík et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9c2https://doi.org/10.1182/blood-2025-4581
View Full Paper
Ask AI
Bookmark
Share